Tauklarify (florquinitau F 18)

Approved uses

To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology

Common questions

What is Tauklarify approved to treat?

According to its FDA label, Tauklarify (florquinitau F 18) is approved for: To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Tauklarify?

Tauklarify (florquinitau F 18) belongs to the tau PET radiopharmaceutical class of medications.

Is there a generic version of Tauklarify?

Not yet. As of the most recent FDA data we ingest, no A-rated generic equivalent is listed for Tauklarify. Availability changes as patents expire.

Does Tauklarify have a Boxed Warning?

Our ingest of the FDA label for Tauklarify (florquinitau F 18) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

Is Tauklarify currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Tauklarify (florquinitau F 18) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Tauklarify approved by the FDA?

The FDA record lists the approval date for Tauklarify (florquinitau F 18) as 2026-08-13.